Show simple item record

dc.contributor.authorVidal, L
dc.contributor.authorAttard, G
dc.contributor.authorKaye, S
dc.contributor.authorDe Bono, J
dc.date.accessioned2018-06-25T15:23:21Z
dc.date.issued2004-11
dc.identifier.citationJournal of chemotherapy (Florence, Italy), 2004, 16 Suppl 4 pp. 7 - 12
dc.identifier.issn1120-009X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1918
dc.identifier.eissn1973-9478
dc.identifier.doi10.1179/joc.2004.16.supplement-1.7
dc.description.abstractThe development of molecular targeted anticancer drugs is rapidly changing cancer therapeutics. However, drug resistance to these novel agents remains a real clinical concern. Reports now indicate that resistance to many of these molecular targeted agents--including hormone therapies, trastuzumab, imatinib, and gefitinib--occurs via common resistance mechanisms. These include 1) inadequate target blockade due to sub-optimal drug delivery; 2) altered target expression at the DNA (gene amplification), mRNA or protein level; 3) an altered target such as a mutated kinase domain; 4) modified target regulating proteins (e.g. altered expression of co-activators and/or co-repressors for nuclear steroid hormone receptors); 5) signalling by alternative proteins (functional redundancy) or different signalling pathways. It is envisioned that the molecular evaluation of clinical anticancer drug resistance, which requires the detailed study of pharmacokinetics, pharmacogenetics and pharmacodynamics, will allow the development of rational reversal strategies and improved patient outcome.
dc.formatPrint
dc.format.extent7 - 12
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectBenzamides
dc.subjectPiperazines
dc.subjectPyrimidines
dc.subjectQuinazolines
dc.subjectAntineoplastic Agents
dc.subjectAntineoplastic Agents, Hormonal
dc.subjectAntibodies, Monoclonal
dc.subjectDrug Delivery Systems
dc.subjectRisk Assessment
dc.subjectSensitivity and Specificity
dc.subjectDrug Resistance, Multiple
dc.subjectDrug Resistance, Neoplasm
dc.subjectFemale
dc.subjectMale
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectImatinib Mesylate
dc.subjectTrastuzumab
dc.subjectGefitinib
dc.titleReversing resistance to targeted therapy.
dc.typeJournal Article
rioxxterms.versionofrecord10.1179/joc.2004.16.supplement-1.7
rioxxterms.licenseref.startdate2004-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of chemotherapy (Florence, Italy)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.publication-statusPublished
pubs.volume16 Suppl 4
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamMedicine Drug Development Unit (Kaye)en_US
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorKaye, Stanley Bernarden
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorAttard, Gerhardten


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record